Vericel (VCEL) FCF Margin (2011 - 2026)

Vericel (VCEL) posted FCF Margin of 18.67% for Q2 2026, down 14.38% sequentially from 21.81% in Q1 2026, and up 1854.0% YoY from 0.96% in Q2 2025.

Analysis

Vericel (VCEL) FCF Margin (2011 - 2026) Analysis & Trends

Vericel has reported FCF Margin for 16 years, with the latest figure at 18.67% in Q2 2026.

Quarterly FCF Margin rose 1854.0% year-over-year to 18.67% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 20.13% (up 2346.0% YoY) and the FY2025 annual result came in at 8.96%, up 1141.0% from the prior year.
FCF Margin eased to 18.67% in Q2 2026 per VCEL's latest filing, from 21.81% in the prior quarter.
Over five years, FCF Margin peaked at 28.82% in Q3 2025 and troughed at 15.93% in Q3 2024.
A 5-year average of 6.07% and a median of 5.22% in 2022 frame the typical range for FCF Margin.
The sharpest annual moves came in 2024 and 2025: FCF Margin slumped 2689 bps in 2024, then soared 4475 bps in 2025.
Over 5 years, FCF Margin stood at 10.67% in 2022, then slumped by 68 bps to 3.46% in 2023, then soared by 224 bps to 11.22% in 2024, then rose by 23 bps to 13.8% in 2025, then soared by 35 bps to 18.67% in 2026.
According to Business Quant data, FCF Margin over the past three periods registered 18.67%, 21.81%, and 13.8% for Q2 2026, Q1 2026, and Q4 2025 respectively.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	13.35%
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	-388.28%
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	25.68%
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	22.62%
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	70.82%
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	-22.35%
10	Vericel	2.05 Bn	1.89 Bn	56.40 Mn	18.67%

Historic Data

Download Data